Loading...
•
Dec 31, 2024
Agios Q4 2024 Earnings Report
Agios reported Q4 2024 earnings, highlighting PYRUKYND net revenue of $10.7 million and cash, cash equivalents, and marketable securities of $1.5 billion.
Key Takeaways
Agios Pharmaceuticals reported Q4 2024 financial results with PYRUKYND net revenue of $10.7 million. The company's cash, cash equivalents, and marketable securities totaled $1.5 billion as of December 31, 2024. Agios completed enrollment for the Phase 3 RISE UP study of Mitapivat in Sickle Cell Disease and filed for regulatory approval of Mitapivat for the treatment of adult patients with thalassemia in multiple regions.
PYRUKYND generated $10.7 million in net revenue, a 20% increase from Q3 2024.
Regulatory applications for mitapivat (PYRUKYND) were filed for the treatment of adult patients with thalassemia.
Enrollment completed for the Phase 3 RISE UP study of mitapivat in sickle cell disease.
Cash, cash equivalents, and marketable securities totaled $1.5 billion as of December 31, 2024.
Forward Guidance
Agios expects to achieve key milestones in 2025, including receiving an FDA regulatory decision for PYRUKYND in thalassemia and announcing topline results from the Phase 3 RISE UP study of mitapivat in sickle cell disease.
Positive Outlook
- Receive FDA regulatory decision for PYRUKYND for thalassemia (PDUFA goal date is September 7, 2025).
- Announce topline results from the Phase 3 RISE UP study of mitapivat in sickle cell disease in late 2025.
- Begin patient enrollment for the Phase 2 study of tebapivat in sickle cell disease in mid-2025.
- Complete patient enrollment in the Phase 2b study of tebapivat for LR-MDS in late 2025.
- File an Investigational New Drug Application for AG-236 in mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...